Tirzepatide vs Retatrutide: Dual vs Triple Agonist

Retatrutide is the leading next-generation contender — a triple agonist (GLP-1 + GIP + glucagon) from Eli Lilly. It's not FDA-approved yet, but the phase 2 weight-loss numbers are eye-popping. Here's how it actually compares to tirzepatide.

01 At a glance

02 Dual vs triple agonist

Tirzepatide and retatrutide both target the same two incretin receptors (GLP-1 and GIP) — but retatrutide adds a third: glucagon.

The glucagon arm

Glucagon is the hormone usually thought of as the opposite of insulin: it raises blood sugar by mobilizing glucose from the liver. So why would a weight-loss drug agonize glucagon? Because glucagon also increases energy expenditure — your basal metabolic rate goes up. The trick of retatrutide's design is balancing the GLP-1/GIP weight loss effect with the glucagon-driven metabolic boost, while keeping blood sugar regulation in check via the GLP-1/GIP arms.

On paper, this is a smarter mechanism than dual agonism. In phase 2 data, it appears to work: retatrutide delivers more weight loss in less time than tirzepatide does. Whether that translates to phase 3 outcomes — and whether the side-effect profile remains acceptable — remains to be seen.

03 Weight loss data

The published phase 2 retatrutide trial (Jastreboff et al., NEJM 2023) randomized 338 adults with obesity (BMI ≥30) to placebo, 1 mg, 4 mg, 8 mg, or 12 mg weekly for 48 weeks. Results:

For reference, tirzepatide 15 mg in SURMOUNT-1 achieved 20.9% loss over 72 weeks. Retatrutide hit 24.2% in 48 weeks. Faster and deeper loss, in a much shorter trial. The phase 3 TRIUMPH program (ongoing) will tell us whether the magnitude holds at 72+ weeks and in larger populations.

04 Availability and timeline

As of April 2026:

• Retatrutide is not FDA-approved. The TRIUMPH phase 3 program (multiple parallel trials) is ongoing — TRIUMPH-1 (general obesity), TRIUMPH-2 (obesity + T2D), TRIUMPH-3 (obesity + cardiovascular disease), and TRIUMPH-4 (sleep apnea).
• Expected approval: late 2026 to 2027 if phase 3 results match phase 2.
• Compounded retatrutide is appearing in some telehealth providers, but the active pharmaceutical ingredient supply chain is less mature, quality assurance is less established, and the regulatory clarity is much lower than for compounded tirzepatide. Several states have explicitly cautioned against compounding it.

For most patients in 2026, the practical answer is: tirzepatide is available now, retatrutide isn't quite. If you start tirzepatide today, you can switch to retatrutide later if it gets approved and offers meaningful additional benefit.

05 Side effects

In phase 2, retatrutide produced GI side effects similar in type to tirzepatide — nausea, diarrhea, vomiting, constipation — but with somewhat higher rates at the maximum 12 mg dose. The glucagon arm may also contribute to:

• Increased heart rate (a few beats per minute on average)
• Mild blood-sugar rises in non-diabetics (offset by the GLP-1/GIP arms)
• Possible additional liver fat reduction (potentially beneficial)

The full safety picture awaits phase 3 readouts. Tirzepatide's safety database (multi-year, post-marketing) is currently far more mature.

06 Switching from tirzepatide to retatrutide

There is no FDA-approved protocol because retatrutide isn't FDA-approved. The off-label / compounded route, where it exists, generally follows:

1. Stop tirzepatide for at least 1 week.
2. Start retatrutide at the lowest available dose (typically 0.5–2 mg).
3. Re-titrate weekly or every 2 weeks based on tolerance.
4. Watch for heart rate and GI symptoms.

Most people considering this switch don't need to. If you're tolerating tirzepatide and meeting your goals, the marginal benefit of a not-yet-approved alternative with limited quality assurance is small. If you've plateaued at 15 mg tirzepatide and want more, the more conservative option is to address the non-drug variables (protein, sleep, NEAT, training, alcohol) before switching agents.

07 What about mazdutide and orforglipron?

Two other "next-gen" agents people compare to tirzepatide:

Mazdutide

A GLP-1 + glucagon dual agonist (no GIP) developed by Innovent Biologics in China. Phase 3 results (DREAMS-1) showed approximately 14–16% mean weight loss at the highest dose. Approved in China but not in the US.

Orforglipron

Eli Lilly's oral, small-molecule GLP-1 agonist — non-peptide, so it can be taken as a pill without food restrictions (unlike Rybelsus). Phase 3 ATTAIN program showed approximately 14–16% weight loss at the highest dose. FDA approval expected late 2026. Less effective than injectable tirzepatide but the convenience of a daily pill is genuinely transformative for some patients.

See our oral / pill tirzepatide page for more on the oral GLP-1 landscape.

08 Tirzepatide vs retatrutide FAQ

Related comparisons